Chengdu Aurine Biotech Resubmits Hong Kong IPO Application on June 30

According to Hong Kong Exchanges and Clearing (HKEX) disclosure on June 30, Chengdu Aurine Biotech Co., Ltd. (ticker: 688319.SH) submitted a main board listing application to HKEX, marking its second submission for Hong Kong listing. China Securities International serves as sole sponsor. The biotech firm specializes in innovative vaccine research, development, production, and commercialization, focusing on two core areas: "superbacterial vaccines" and "adult vaccines," with an established sales network spanning 30 Chinese provinces and regions.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments